Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APTBCy: Optimized GVHD Prophylaxis in Myeloid Malignancies
NCT07238712Phase 2Recruiting
- Sponsor
- First Saint Petersburg State Medical University
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib, abatacept in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), Atypical chronic myeloid leukemia (aCML), sponsored by First Saint Petersburg State Medical University. Started May 2025; status: recruiting.
02
Drugs
ruxolitinibabatacept
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)Atypical chronic myeloid leukemia (aCML)
Beyond the preview
Go deeper on NCT07238712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07238712.